NCT06607185 Cancer Clinical Trial

PIPELINE > TRIAL OVERVIEW

Phase

Enrolling

A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors^a

Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic solid tumor cancer
Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA
Have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
Must be able to swallow tablets
Select cohorts must have received ≥1 prior line of systemic chemotherapy for advanced or metastatic disease

Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Participants with asymptomatic or treated CNS disease may be eligible
Have unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1 at the time of starting trial treatment, except for alopecia, peripheral neuropathy, and ongoing endocrinopathies controlled on appropriate replacement therapy
Have significant cardiovascular disease defined as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction or heart failure, uncontrolled or symptomatic arrhythmias
Have known active hepatitis B, hepatitis C, or untreated HIV
Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
Have other active malignancies unless in remission with life expectancy >2 years
Have history of non-infectious pneumonitis/interstitial lung disease (ILD) that required steroids or has current clinically significant pneumonitis/ILD

This clinical trial is currently being conducted in the United States and Japan.

Administered orally.

Administered intravenously.

For information on trial enrollment, locations, and more, call 1-800-545-5979.

or visit www.clinicaltrials.gov for more information on this trial